ASH 2022 | Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line setting

Elias Jabbour • 5 Dec 2022

ASH 2022

Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, explains the results of a retrospective analysis investigating the outcomes of third-line tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP). The study demonstrated a substantial benefit in progression-free survival (PFS) and overall survival (OS) for patients treated with ponatinib when compared to patients treated with second-generation TKIs (2G-TKIs), thereby supporting the use of ponatinib as a standard of care (SOC) in the third-line setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Takeda: Other: Advisory Role, Research Funding; Genentech: Other: Advisory Role, Research Funding; Adaptive Biotechnologies: Other: Advisory Role, Research Funding; Spectrum: Research Funding; Pfizer: Other: Advisory Role, Research Funding; Bristol Myers Squibb: Other: Advisory Role, Research Funding; Amgen: Other: Advisory Role, Research Funding; AbbVie: Other: Advisory Role, Research Funding.